



**MEDICARE ADVANTAGE  
PRIOR AUTHORIZATION REQUEST FORM**

Adempas

Phone: 215-991-4300

Fax back to: 866-371-3239

Jefferson Health Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

**PLEASE NOTE: Any information (patient, prescriber, drug, labs) left blank, illegible, or not attached WILL delay the review process.**

<b>Member Name:</b>	<b>Prescriber Name:</b>	
Member Number:	Fax:	Phone:
Date of Birth:	Office Contact:	
Line of Business: <input type="checkbox"/> Medicare Advantage	NPI:	State Lic ID:
Address:	Address:	
City, State ZIP:	City, State ZIP:	
Primary Phone:	<b>Specialty/facility name (if applicable):</b>	

**REQUEST FOR EXPEDITED REVIEW:** By checking this box and signing below, I certify that applying the 72 hour standard review timeframe may seriously jeopardize the life or health of the enrollee or the enrollee's ability to regain maximum function.

Drug Name:	
Strength:	
Directions / SIG:	

**Please attach any pertinent medical history including labs and information for this member that may support approval.**

**Please answer the following questions and sign.**

**Q1. Is this request for reauthorization?**

Yes  No

**Q2. Is there confirmation of positive clinical response to therapy or stabilization?**

Yes  No

**Q3. Is Adempas being prescribed by or in consultation with a cardiologist, pulmonologist, or practitioner at a Pulmonary Hypertension Association-Accredited center?**

Yes  No

**Q4. Is the patient 18 years of age or older?**

Yes  No

**Q5. Is the patient female and of reproductive potential?**

Yes  No



**MEDICARE ADVANTAGE  
PRIOR AUTHORIZATION REQUEST FORM**

Adempas

Phone: 215-991-4300

Fax back to: 866-371-3239

Jefferson Health Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

**PLEASE NOTE: Any information (patient, prescriber, drug, labs) left blank, illegible, or not attached WILL delay the review process.**

<b>Member Name:</b>	<b>Prescriber Name:</b>
<p>Q6. Did the patient have a negative pregnancy test and enroll in the manufacturer's risk evaluation and mitigation strategy (REMS) program prior to initiating Adempas?</p> <p><input type="checkbox"/> Yes      <input type="checkbox"/> No</p>	
<p>Q7. Does the member have the diagnosis of World Health Organization (WHO) Group 1 pulmonary arterial hypertension (PAH)?</p> <p><input type="checkbox"/> Yes      <input type="checkbox"/> No</p>	
<p>Q8. Has the diagnosis of PAH been confirmed by a complete right catheterization (RHC) (please attach RHC report)? PAH is defined as:I. A mean pulmonary arterial pressure (mPAP) greater than 20 mmHg; II. A pulmonary capillary wedge pressure (PCWP) less than or equal to 15 mmHg ; III. A pulmonary vascular resistance (PVR) greater than 2 Wood units?</p> <p><input type="checkbox"/> Yes      <input type="checkbox"/> No</p>	
<p>Q9. Does the patient have WHO functional class II (Slight limitation of physical activity but comfortable at rest. Ordinary physical activity causes undue dyspnea or fatigue, chest pain, or near syncope) or III (Marked limitation of physical activity and comfortable at rest. Less than ordinary activity causes undue dyspnea or fatigue, chest pain, or near syncope)?</p> <p><input type="checkbox"/> Yes      <input type="checkbox"/> No</p>	
<p>Q10. Does the member have the diagnosis of World Health Organization (WHO) Group 4 PAH?</p> <p><input type="checkbox"/> Yes      <input type="checkbox"/> No</p>	
<p>Q11. Is there documentation confirming the diagnosis of chronic thromboembolic pulmonary hypertension (CTEPH) and verifying patient has recurrent or persisting pulmonary hypertension following pulmonary thromboendarterectomy or inoperable CTEPH?</p> <p><input type="checkbox"/> Yes      <input type="checkbox"/> No</p>	
<p>Q12. Will Adempas be used with nitrates, nitric oxide donors, or phosphodiesterase inhibitors OR is the patients pulmonary hypertension associated with idiopathic interstitial pneumonia (PH-IIP)?</p> <p><input type="checkbox"/> Yes      <input type="checkbox"/> No</p>	

This telecopy transmission contains confidential information belonging to the sender that is legally privileged. This information is intended only for the use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or action taken in reference to the contents of this document is strictly prohibited. If you have received this telecopy in error, please notify the sender immediately to arrange for the return of this document.



**MEDICARE ADVANTAGE  
PRIOR AUTHORIZATION REQUEST FORM**

Adempas

Phone: 215-991-4300

Fax back to: 866-371-3239

Jefferson Health Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

**PLEASE NOTE: Any information (patient, prescriber, drug, labs) left blank, illegible, or not attached WILL delay the review process.**

<b>Member Name:</b>	<b>Prescriber Name:</b>
---------------------	-------------------------

**Q13. Requested Duration:**

12 Months

Other:

**Q14. Additional Information:**

Prescriber Signature

Date

v2026